Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.
2.

Phasor plotting with frequency-domain flow cytometry.

Cao R, Jenkins P, Peria W, Sands B, Naivar M, Brent R, Houston JP.

Opt Express. 2016 Jun 27;24(13):14596-607. doi: 10.1364/OE.24.014596.

PMID:
27410612
3.

Evaluation of the catalytic activity and cytotoxicity of palladium nanocubes: the role of oxygen.

Dahal E, Curtiss J, Subedi D, Chen G, Houston JP, Smirnov S.

ACS Appl Mater Interfaces. 2015 May 13;7(18):9364-71. doi: 10.1021/am509124x. Epub 2015 Apr 30.

4.

Toward the measurement of multiple fluorescence lifetimes in flow cytometry: maximizing multi-harmonic content from cells and microspheres.

Jenkins P, Naivar MA, Houston JP.

J Biophotonics. 2015 Nov;8(11-12):908-17. doi: 10.1002/jbio.201400115. Epub 2015 Feb 26.

5.

Measuring and sorting cell populations expressing isospectral fluorescent proteins with different fluorescence lifetimes.

Sands B, Jenkins P, Peria WJ, Naivar M, Houston JP, Brent R.

PLoS One. 2014 Oct 10;9(10):e109940. doi: 10.1371/journal.pone.0109940. eCollection 2014 Oct 10.

6.

Expanding the potential of standard flow cytometry by extracting fluorescence lifetimes from cytometric pulse shifts.

Cao R, Naivar MA, Wilder M, Houston JP.

Cytometry A. 2014 Dec;85(12):999-1010. doi: 10.1002/cyto.a.22574. Epub 2014 Oct 1.

7.

Fluorescence lifetime excitation cytometry by kinetic dithering.

Li W, Vacca G, Castillo M, Houston KD, Houston JP.

Electrophoresis. 2014 Jul;35(12-13):1846-54. doi: 10.1002/elps.201300618. Epub 2014 May 12.

8.

Subcellular localization-dependent changes in EGFP fluorescence lifetime measured by time-resolved flow cytometry.

Gohar AV, Cao R, Jenkins P, Li W, Houston JP, Houston KD.

Biomed Opt Express. 2013 Jul 19;4(8):1390-400. doi: 10.1364/BOE.4.001390. eCollection 2013 Jul 19.

9.

Cytometric sorting based on the fluorescence lifetime of spectrally overlapping signals.

Cao R, Pankayatselvan V, Houston JP.

Opt Express. 2013 Jun 17;21(12):14816-31. doi: 10.1364/OE.21.014816.

10.

Association of candidate gene polymorphisms with diastolic blood pressure change in patients treated with duloxetine.

Fijal BA, Kohler J, Ostbye K, Ahl J, Houston JP.

Psychiatry Res. 2013 Apr 30;206(2-3):313-4. doi: 10.1016/j.psychres.2012.10.019. Epub 2012 Dec 11.

PMID:
23245538
11.

A cross-validation of the provisional diagnostic instrument (PDI-4).

Faries DE, Houston JP, Sulcs EM, Swindle RW.

BMC Fam Pract. 2012 Oct 15;13:104. doi: 10.1186/1471-2296-13-104.

12.

Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.

Houston JP, Kohler J, Bishop JR, Ellingrod VL, Ostbye KM, Zhao F, Conley RR, Poole Hoffmann V, Fijal BA.

J Clin Psychiatry. 2012 Aug;73(8):1077-86. doi: 10.4088/JCP.11m06916.

PMID:
22967772
13.

Evaluation of genetic models for response in a randomized clinical trial of duloxetine in major depressive disorder.

Houston JP, Zou W, Aris V, Fijal B, Chen P, Heinloth AN, Martinez J.

Psychiatry Res. 2012 Nov 30;200(1):63-5. doi: 10.1016/j.psychres.2012.06.002. Epub 2012 Jun 22.

PMID:
22727709
14.

Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: a candidate gene analysis.

Houston JP, Lau K, Aris V, Liu W, Fijal BA, Heinloth AN, Perlis RH.

J Clin Psychiatry. 2012 Jun;73(6):878-85. doi: 10.4088/JCP.10m06744. Epub 2012 Mar 6.

PMID:
22480387
15.

Pharmacogenetic investigation of response to duloxetine treatment in generalized anxiety disorder.

Perlis RH, Fijal B, Dharia S, Houston JP.

Pharmacogenomics J. 2013 Jun;13(3):280-5. doi: 10.1038/tpj.2011.62. Epub 2012 Jan 17.

PMID:
22249355
16.

Capture of Fluorescence Decay Times by Flow Cytometry.

Houston JP, Naivar MA, Jenkins P, Freyer JP.

Curr Protoc Cytom. 2012;59(125):1.25.1-1.25.21.

17.

PDI-4A: an augmented provisional screening instrument assessing 5 additional common anxiety-related diagnoses in adult primary care patients.

Houston JP, Kroenke K, Davidson JR, Adler LA, Faries DE, Ahl J, Swindle R, Trzepacz PT.

Postgrad Med. 2011 Sep;123(5):89-95. doi: 10.3810/pgm.2011.09.2463.

PMID:
21904090
18.

Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.

Fijal BA, Stauffer VL, Kinon BJ, Conley RR, Hoffmann VP, Witte MM, Zhao F, Houston JP.

J Clin Psychiatry. 2012 Mar;73(3):367-71. doi: 10.4088/JCP.10m06507. Epub 2011 Jul 12.

PMID:
21813073
19.

Association of catechol-O-methyltransferase variants with duloxetine response in major depressive disorder.

Houston JP, Kohler J, Ostbye KM, Heinloth A, Perlis RH.

Psychiatry Res. 2011 Oct 30;189(3):475-7. doi: 10.1016/j.psychres.2011.07.002. Epub 2011 Jul 24.

PMID:
21788083
20.

A provisional screening instrument for four common mental disorders in adult primary care patients.

Houston JP, Kroenke K, Faries DE, Doebbeling CC, Adler LA, Ahl J, Swindle R, Trzepacz PT.

Psychosomatics. 2011 Jan-Feb;52(1):48-55. doi: 10.1016/j.psym.2010.11.011.

PMID:
21300195

Supplemental Content

Loading ...
Support Center